RxDoctor Payments Data

Marwan Hilal, MD

Internal Medicine · Garfield Heights, OHNPI 1154308781

Payments from drug & device makers

$3,402in general payments, 2019–2025

Across 60 payments — averaging $56.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$716
  • Boehringer Ingelheim$432
  • Esperion Therapeutics, Inc.$350
  • AbbVie$320
  • Phathom Pharmaceuticals, Inc.$240
  • Novartis$224
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$3,402100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,402 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$33,753
Medicare patients
128
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$107,026
EliquisApixaban91$90,466
OzempicSemaglutide40$73,371
FarxigaDapagliflozin Propanediol83$69,364
XareltoRivaroxaban18$23,791
CreonLipase/Protease/Amylase28$17,778
Enoxaparin Sodium15$14,404
LinzessLinaclotide17$9,429
NexletolBempedoic Acid15$8,505
JanuviaSitagliptin Phosphate12$6,366
Combivent RespimatIpratropium/Albuterol Sulfate13$6,196
DuleraMometasone/Formoterol11$3,886
Atorvastatin Calcium257$3,344
Gabapentin191$3,145
Baclofen157$2,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$432$113,22298 claims
PfizerEliquis$51$90,46691 claims
Novo NordiskOzempic$150$73,37140 claims
AstraZenecaFarxiga$716$69,36483 claims
AbbVieCreon, Linzess$320$27,20745 claims
Esperion Therapeutics, Inc.Nexletol$350$8,50515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Garfield Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →